Roche to present new data advancing its obesity portfolio at the American Diabetes Associations 2026 Scientific Sessions 2026-06-01 Late-breaking Phase II data highlight enicepatides (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintides efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity A Phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated towards mid-2026 to develop a differentiated treatment option Basel, 1 June 2026 - Roche (SIX: RO, ROP
Similarly, T47D cells have also previously been reported to be devoid of mature GSTO1 (ref
Get Started Today Get Started Begin Your Regeneration Schedule a consultation with our medical team to learn if GHK-Cu copper peptide therapy is right for your skin health, tissue repair, and regenerative goals
At JosephCareRX, our weight specialists are dedicated to providing our patients with the latest and most effective treatment options for managing type 2 diabetes and supporting healthy weight loss
Guaranteed analysis: This is where you'll find the percentages of the most important nutrients in the food: protein, fat, fiber, and moisture
